You are now leaving this site.

You are about to leave a ViiV Healthcare website. By clicking “Continue,” you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.

  • Patient Profiles
  • Efficacy and Resistance
    • Efficacy and Resistance
    • Treatment-Naïve Data
    • Switch Data
  • Safety
  • Patient Experience
  • Dosing
  • Samples and Savings
  • Resources
    • Resources
    • Educational Resources
    • Webinars
    • Connect With Us
  • Home

    Patient Profiles

    Efficacy and Resistance

    • Treatment-Naïve Data
      • DOVATO vs 3DR to 3 Years
      • ART-Naïve Patients With CD4+ Count ≤200
    • Switch Data
      • DOVATO vs TAF Regimens to 4 Years
      • DOVATO vs Continuing BIKTARVY
      • DOVATO vs BIKTARVY—Dual Switch

    Safety

    Patient Experience

    Dosing

    Samples and Savings

    Resources

    • Resources
    • Educational Resources
    • Webinars
    • Connect With Us

    PMUS-DLLWCNT250023 March 2026

    INDICATION

    DOVATO is indicated as a complete regimen to treat HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of DOVATO.

    ${_.BottomText2}

    To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    BIKTARVY and GENVOYA are trademarks of Gilead Sciences, Inc. All other trademarks are owned by or licensed to the ViiV Healthcare group of companies.

    This site is funded and developed by ViiV Healthcare.
    This site is intended for US healthcare professionals only.
    ©2026 ViiV Healthcare or licensor.
    PMUS-DLLWCNT250023 March 2026
    Produced in USA.

    Cookie banner
  • Terms of Use
  • Privacy Notice
  • Patient Support
  • Interest-based Ads
  • Contact Us
  • ViiV Medical Information
  • Site Map
  • Unsubscribe